

## New BRAF knock-in mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome

### Associate Professor AOKI, Yoko

Dr. Yoko Aoki's research group has been studying the molecular mechanisms for RASopathies, a group of phenotypically overlapping syndromes caused by germline mutations that encode components of the RAS-MAPK pathway. They, in collaboration with Prof. Ogura's group (Institute of Development, Aging and Cancer, Tohoku University), generated and analyzed knock-in mice expressing the *Braf* Q241R mutation, which corresponds to the most frequent mutation in cardio-facio-cutaneous (CFC) syndrome, Q257R. *Braf*<sup>Q241R/+</sup>;Cre mice manifested embryonic/neonatal lethality, showing liver necrosis, edema, craniofacial abnormalities, thickened cardiac valves, ventricular noncompaction and ventricular septal defects, which recapitulate the major phenotypes of CFC syndrome. Prenatal treatment with a MEK inhibitor, PD0325901, rescued the embryonic lethality with amelioration of craniofacial abnormalities and edema in *Braf*<sup>Q241R/+</sup>;Cre embryos. Combination treatment with PD0325901 and a histone 3 demethylase inhibitor (GSK-J4) further increased the rescue from embryonic lethality, ameliorating enlarged cardiac valves. These results suggest that the new BRAF knock-in mice recapitulate major features of RASopathies and that epigenetic modulation as well as the inhibition of the ERK pathway will be a potential therapeutic strategy for the treatment of RASopathies.




**Associate Professor  
AOKI, Yoko**


Medical Genetics

aokiy@med.tohoku.ac.jp

<http://www.med.tohoku.ac.jp/english/org/medical/30/index.html>



**Figure 1.** RASopathies. *BRAF*, *MAP2K1/2* or *KRAS* mutations have been identified in individuals with CFC syndrome.



**Figure 2.** Heart defects observed in *Braf*<sup>Q241R/+</sup>; Cre embryos at E16.5.

## New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.

Inoue SI, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, Aoki Y.

*Hum Mol Genet.* 2014 Jul 17. pii: ddu376. [Epub ahead of print]